

The background is a solid blue color with a pattern of white and light blue hexagons of various sizes and orientations. A vertical white line is positioned to the left of the main text.

# FY | Annual 23 | Result

28 February 2024

**NEXT SCIENCE<sup>®</sup>**

# About Next Science



## X BIO™ Platform

deconstructs, destroys, & defends against biofilm growth and recolonisation



## 7 Product Families

Across wound and surgical applications



## TAM >US\$12.5bn

Across existing products<sup>1</sup>



## Surgical

Higher direct sales, GPO contract drive XPERIENCE<sup>®</sup> penetration



## Wound Care

DME and BLASTX<sup>®</sup> drives penetration into advanced wound care



## Distribution

Direct and partner channels with increasing focus on direct channel




## Intellectual Property

56 patents and 20 publications



## Regulatory Approvals

Multiple FDA cleared and commercialised products



## Employee Headcount

108 – 47 Sales, 22 R&D

1. Total Addressable Market (TAM) based on National Health Statistics Report, February 2017, SmartTRAK, NXS

# FY23 Financial Highlights



**Revenue**

**US\$22.2m**

+ US\$10.5m or 89% yoy



**Gross Profit**

**US\$16.2m**

+US\$7.1m or 77% yoy



**Gross Margin**

**73% (H2 FY23: 78%)**

FY22: 78%



**EBITDA Loss**

**(US\$14.8m)**

FY22: (US\$11.8m)



**Direct Product Sales**

**US\$16.9m (76% of product sales)**

+US\$11.2m or 195% yoy



**Product Sales**

**US\$22.1m**

+US\$10.5m or 90% yoy



**Cash receipts**

**US\$20.1m**

+US\$9.5m or 89% yoy



**Closing Cash**

**US\$9.2m**

FY22: US\$5.1m

# FY23 Operational Achievements

1

Wound Care sales growth reflects changes to Durable Medical Equipment (DME) structure and higher direct sales of BlastX®

2

XPERIENCE® benefits from higher direct sales, increased clinical evidence available and broader access to healthcare sites due to GPO contract

3

Use data analytics and metric-based performance to drive efficiencies and productivity in individual sales force territories

4

Canadian Periprosthetic Joint Infection Study of 7,600 patients commenced recruitment with 302 enrolled patients at first site

5

Board and leadership team renewal brings fresh perspectives, skills and experience to Next Science



# Agenda

- >> Business Overview**
- >> FY23 Financial Result**
- >> Strategy & Outlook**
- >> Appendices**

**I.V. Hall, CEO and Managing Director**

**Marc Zimmerman, CFO**

# Business Overview

# Our Purpose

## Vision

Healing People and Saving Lives

## Mission

Next Science strives to significantly improve patient outcomes, elevate physician efficacy, and create value within the overall healthcare system through relentless innovation and commitment to education and research on biofilm elimination, infection prevention, and treatments for inflammatory diseases.

# XBIO™ - Destroys Biofilm Based Pathogens



Deconstructs the biofilm

Removes metal ions of the EPS<sup>1</sup>, exposing pathogens within the biofilm



Destroys pathogens enveloped within the XBIO™ Technology

High osmolarity environment + cell membrane disaggregation induces lysis of bacteria within the product



Defends against recolonisation

Biofilm matrix cannot reform within the presence of XBIO™

**Unique mechanism of action, with no known resistance from bacteria to XBIO™ technology**

1. Extracellular polymeric substances



# Next Science's Products Serve a US\$12.5bn Market

## Surgical Products

### **XPERIENCE**<sup>®</sup>

**Key Target:** Prevention of surgical site infection

### **SURGX**<sup>®</sup>

**Key Target:** Prevention of infection on a surgical closure

### **Bactisure**<sup>®</sup> **Surgical Lavage**

**Key Target:** Elimination of surgical site infection.

## **XBIO**<sup>™</sup> Platform

Deconstructs biofilm,  
destroys pathogens,  
& defends against  
recolonisation

## Wound Care Products

### **BLASTX**<sup>®</sup>

**Key Target:** Treatment of chronic wounds, foot & leg ulcers, pressure ulcers.

### **Collagen with BLASTX**<sup>®</sup>

**Key Target:** Treatment of chronic wounds, complementary to BLASTX.

### **Acne Treatments**

**Key Target:** Treatment of acne and breakouts. Online and retail in ANZ

# XBIO™ - Surgical Site Infection Prevention

## XPERIENCE<sup>®</sup> positioned to challenge surgical Standard of Care

*Advanced surgical irrigation solution for surgical procedures*

### Key features


- 5+ hours of broad-spectrum efficacy bacteria and other microorganisms
- No rinse out required
- Biocompatible
- No change to surgical protocol
- Compatible with all implants

### Forthcoming study results expected to confirm benefits for Patients, Surgeons and Hospitals

- **Patients:** Lower risk of surgical site infection and reduced inflammation leads to less pain and reduced opioid use <sup>1</sup>
- **Surgeons:** Better patient experience, reduce re-admissions
- **Hospitals:** Cost savings through lower re-admission rates

**Market opportunity via 48m annual surgeries in the US<sup>2</sup>**

Growing clinical data base on XPERIENCE<sup>®</sup> may have cross fertilisation benefits into the wound care market



A knee washed out with Saline prior to implant placement



A knee at the same time in surgery washed out with XPERIENCE<sup>®</sup>

1. ASX – 9/8/23 - Prospective randomised study with 30 patients in each arm of the knee study trial, demonstrating potential anti-inflammatory benefits of XPERIENCE  
2. National Health Statistics Report February 2017

# XBIO™ Improves Treatment of Chronic Wounds

## BLASTX® Antimicrobial Wound Gel improves wound management

### Key characteristics include:

- Broad spectrum of efficacy
- Biocompatible and prevents bacterial growth within gel
- Provides a moist wound environment conducive to healing

### Indications

- Stage I – IV pressure ulcers
- Partial and full-thickness wounds
- Diabetic foot and leg ulcers
- Post-surgical wounds
- First and second-degree burns
- Grafted and donor sites

Spontaneous rupture of traumatic hematoma in lower leg. Wound 8 weeks old when treatment commenced. High risk of severe infection



Differentiation: treatment regimen is flexible across all wound types and bacteria. Provides an answer to chronic wounds. Improves outcomes under NPWT. Some wounds may not proceed to tissue

# Continued progress on key priorities

## Drive XPERIENCE® Penetration



## Expansion of DME



## Growth in Distribution



## Innovation

- **Distribution:** Utilise GPO access to drive new accounts, and expand field representation
- **Research:** Leverage research findings in existing accounts as well as new accounts to increase usage
- **Product:** Widen the XPERIENCE® formats to support a wider customer base

- **Distribution:** Drive growth into Wound Care Centres, Long Term Acute Care, and Skilled Nursing Facility
- Implement second site for fulfilment of DME orders

- Accelerate the product pipeline for increased sales value on existing distribution networks
- Accelerate growth opportunities with existing partners

- Determine pathways for patented developments of other applications of XBIO™ technology

# FY23 Financial Result





- **Record revenue of US\$22.2m, up 89% yoy** with significant growth in the Wound Care and Surgical businesses reflecting focus on direct sales and the first full year of the DME structure
- **Gross Profit of US\$16.2m, up 77% yoy** and up 97% in H2 FY23 on pcp. This reflected improvements in revenue quality and purchasing power as the DME structure continues to scale
- **Gross Margin of 73%** improved through the year with H2 FY23 GM% of 78% compared to 68% in H1 FY23 (FY22: 78%)
- **Operating expenses up 48% yoy** mainly reflecting the 96% growth in Selling & Distribution Expenses as Next Science increased investment in its direct sales team
- **Research & Development expenses up 4% yoy** largely due to investment in clinical studies including the 7,600 patient Canadian prospective study on infection prevention. H2 FY23 R&D expenses were 9% lower compared to H1 FY23
- **EBITDA loss of (US\$14.8m)** compared to (US\$11.8m) in FY22 as strong revenue growth was offset by increased investment in the direct sales force to drive future revenue
- **Operating loss of (US\$16.0m)** compared to (US\$12.7m) in FY22

Financial Summary (US\$m)	FY22	FY23	\$ Change	% Change
<b>Revenue</b>	<b>11.7</b>	<b>22.2</b>	<b>10.5</b>	<b>89%</b>
Cost of Sales	(2.6)	(5.9)	(3.4)	132%
<b>Gross Profit</b>	<b>9.1</b>	<b>16.2</b>	<b>7.1</b>	<b>77%</b>
<b>Gross Margin</b>	<b>78%</b>	<b>73%</b>	<i>(5bps)</i>	
Other Income	0.0	0.1	0.1	163%
<b>Expenses</b>				
Selling & Distribution	(10.3)	(20.1)	(9.8)	96%
Research & Development	(5.5)	(5.7)	(0.2)	4%
Administration	(5.2)	(5.4)	(0.2)	4%
Other	(0.0)	(0.0)	(0.0)	(41%)
<b>Total Operating Expenses</b>	<b>(21.0)</b>	<b>(31.1)</b>	<b>(10.2)</b>	<b>48%</b>
<b>EBITDA Loss</b>	<b>(11.8)</b>	<b>(14.8)</b>	<b>(3.0)</b>	<b>26%</b>
Depreciation & Amortisation	(0.9)	(1.1)	(0.2)	24%
<b>Operating Loss</b>	<b>(12.7)</b>	<b>(16.0)</b>	<b>(3.1)</b>	<b>26%</b>


\*Note there may be some minor differences due to rounding

\*\* EBITDA Loss of (US\$7.7m) in H1 FY23 and (US\$7.1m) in H2 FY23

# Direct Sales Channel Drives Strong Growth

- **Direct product sales of US\$16.9m, up 195.1% yoy;** 76% of product sales (FY22: 49%) due to success of DME structure introduced in Oct 2022 and higher direct sales of XPERIENCE®
- **H2 FY23 direct product sales of US\$9.7m** (81% of product sales) compared to US\$7.2m in H1 FY23
- **Product sales of US\$22.1m, up 89.6% yoy** as higher direct sales more than offset the decline in partner sales (FY23:US\$5.2m vs FY22:US\$6.0m) which reflected strategic focus on direct channel
- **Direct wound care sales were up 411% yoy** due to a full year of the DME structure and increased focus on revenue quality
- **Direct surgical sales were up 46% yoy** driven by a strong performance by XPERIENCE® up 58% yoy. This reflected the signing of a GPO contract in August 2023 and increased clinical evidence available on the efficacy of XPERIENCE®

Strategic focus on direct sales delivers growth



# Balance Sheet – No Debt Post Raise

- As of 31 December 2023, Next Science had cash of US\$9.2m and no debt
- Growth in receivables and payables mainly relates to the DME business

Balance Sheet (US\$m)	31-Dec 2023	31 Dec 2022
<b>Assets</b>		
Cash and cash equivalents	9.2	5.1
Trade and other receivables	3.6	1.7
Inventories	0.7	0.9
Other current assets	0.4	0.6
<b>Total current assets</b>	<b>14.0</b>	<b>8.3</b>
Trade and other receivables	0.0	0.0
Property, plant and equipment	0.7	0.7
Right-of-use assets	0.8	1.1
Intangible assets	2.4	2.4
<b>Total non-current assets</b>	<b>3.9</b>	<b>4.2</b>
<b>Total assets</b>	<b>17.9</b>	<b>12.5</b>
<b>Liabilities</b>		
Trade and other payables	3.2	2.0
Other current liabilities	0.6	0.6
<b>Total current liabilities</b>	<b>3.8</b>	<b>2.6</b>
Contract liabilities	0.5	0.8
Loans and borrowings	-	-
Other non-current liabilities	0.7	1.0
<b>Total non-current liabilities</b>	<b>1.2</b>	<b>1.8</b>
<b>Total liabilities</b>	<b>5.1</b>	<b>4.4</b>
<b>Net assets / (liabilities)</b>	<b>12.8</b>	<b>8.0</b>



# Record Cash Receipts

- **Record cash receipts of US\$20.1m, up 89% yoy;** H2 FY23 cash receipts of US\$11.0m, up 169% on pcp (US\$6.5m) and up 20% on H1 FY23 (US\$9.1m)
- **Payments to suppliers of US\$33.4m, up 63% yoy;** 2H FY23 cash costs of US\$16.4m, 4% improvement on H1 FY23 (US\$17.0m) as supply chain efficiencies realised as DME structure expands
- **Net Operating Cash Outflow of US\$15.1m in FY23** compared to US\$11.8m in FY22. H2 FY23 net operating cash outflow of US\$7.2m showed improvement on US\$7.8m in H1 FY23 as the DME business scales and the focus on direct sales drives growth
- In September 2023, Next Science completed a capital raise which included the conversion of convertible notes held by Walker Group to raise net proceeds of A\$20.4m
- **Closing cash balance of US\$9.2m** at 31 December 2023

Cash Flow (US\$m)	FY22	FY23
<b>Operating activities</b>		
Receipts from customers	10.7	20.1
Payments to suppliers and employees	(20.5)	(33.4)
Payments for research and development	(2.0)	(1.9)
Interest received	0.0	0.1
Other income	0.0	0.1
<b>Net Cash Used in Operating Activities</b>	<b>(11.8)</b>	<b>(15.1)</b>
<b>Investing activities</b>		
Payments for property, plant and equipment	(0.1)	(0.3)
Payments for intangible assets	(0.4)	(0.6)
(Payments for) / Proceeds from investments	0.3	0.0
<b>Net Cash Used in Investing Activities</b>	<b>(0.1)</b>	<b>(0.9)</b>
<b>Financing activities</b>		
Proceeds from issue of ordinary shares	10.9	14.0
Proceeds from issue of converting notes	-	7.0
Proceeds from conversion of options to ordinary shares	0.0	-
Capital raising costs	(0.4)	(0.6)
Payment of lease liabilities	(0.3)	(0.3)
<b>Net Cash from Financing Activities</b>	<b>10.2</b>	<b>20.1</b>
<b>Net Increase / (decrease) in Cash</b>	<b>(1.7)</b>	<b>4.2</b>
Cash at the Beginning of the Financial Year	7.0	5.1
Exchange rate effects	(0.2)	0.0
<b>Cash at the End of the Financial year</b>	<b>5.1</b>	<b>9.2</b>

# Strategy & Outlook



# Strategic Aspirations

XBIO™ Brand  
Excellence

Total Patient  
Solutions

Gold Standard  
for Infection  
Prevention

Gold Standard  
for Education  
and Science on  
Biofilm

Top Talent  
Destination as a  
Company

Innovation  
beyond SSI and  
Chronic Wounds  
protected by IP

# Strategic Priorities

FY2024 – FY2026

Succeed in Full Orthopaedic Market

Accelerate Penetration in Chronic Wound in Long Term Care Centres

Launch Solution for Wounds due to Hidradenitis Suppurativa (HS)

Crack the code for Military and First Responder Channels



# Outlook

- 1 Increase penetration and productivity of the DME structure and drive further improvement in revenue quality
- 2 Drive higher direct sales of BLASTX® to Long Term Care Centres and Veterans Affairs clinics
- 3 Direct sales of XPERIENCE® expected to benefit from expanded GPO footprint and extension of use case from high risk to prophylactic use
- 4 Consolidation of sales leadership and sales team restructure expected to deliver significant improvements in future productivity and efficiency
- 5 Publication of additional clinical research for BlastX® and XPERIENCE® expected in next 12 months

## FY24 Guidance

- > FY24 Revenue of **US\$36-40m**
- > Expect to be EBITDA and Cashflow positive during H2 FY24

# Appendix



# Clinical Studies - XPERIENCE®

Indication	Product	Study Size	Structure	Sites	Status
Total Knee Arthroplasties	XPERIENCE®	524	Post Operative Infection Retrospective. XP v SoC (iodine)	Principal Investigator -Dr Ronald Singer -The Surgery Centre at Edgewater	Study completed, waiting on publication
Impact of XPERIENCE on Bone Cement Adhesion	XPERIENCE®	In-vitro & Animal study	Clinical and Laboratory collaboration	University of New South Wales And Dr R Bashyal, Chicago	Research paper in write-up phase
Post-op Infection of Primary Joint Replacement	XPERIENCE®	7600	Investigator Research Study. (product donated) XP v 0.3% Betadine	Dr Beale and Dr Garceau Ottawa Hospital Research Institute, Canada Randomised Controlled study over 7 sites in Canada	One site commenced recruitment with 302 patients enrolled. All other sites pending recruitment
Primary, Revision, I&D Hip, Knee, Shoulder Arthroplasties	XPERIENCE®	423	Post Operative Infection Retrospective. XP V SoC. PJI-90 days	Principal Investigator -Dr Robert Harris - Jack Hughston Memorial	Paper written and pending publication
Post-op Infection of Primary Joint Replacement in High-Risk Patients	XPERIENCE®	936	Investigator Research Study (product donated) XP v saline	Dr Mont, Sinai Hospital of Baltimore, MD Dr Scuderi, Northwell Health /Lennox Hill Hospital NY	69/936 patients enrolled
Infection in Long Bone Fracture Fixation	XPERIENCE®	3	Investigator Research Study (product donated) XP v saline	Dr. Zsolt Balogh John Hunter Hospital, NSW, Australia	Awaiting initiation

# Clinical Studies - BLASTX<sup>®</sup>/SURGX<sup>®</sup>

Indication	Product	Study Size	Structure	Sites	Status
Hidradenitis Suppurativa	BLASTX <sup>®</sup>	15	Investigator Research Study. (product donated)	Dr. Hadar Lev-Tov, University of Miami Health, FL	Study completed, pending publication
Pressure Ulcers (previously failed with NPWT)	BLASTX <sup>®</sup>	20	Investigator Research Study. (product donated)	Dr. Thomas Serena, Serena Group, Cambridge, MA	Paper written, pending publication
Total Shoulder Arthroplasties	SURGX <sup>®</sup>	60	Investigator Research Study. (product donated)	Dr. Otto, St. Louis University, MO	Research paper in write-up phase
Primary Hip & Knee Arthroplasties	SURGX <sup>®</sup>	700	Investigator Research Study. (product donated)  SoC + SURGX v SoC alone	Dr Mont, Sinai Hospital of Baltimore, MD  Dr Scuderi, Northwell Health /Lennox Hill Hospital NY	Currently enrolling



# Upcoming Clinical Publications - XPERIENCE®

Indication	Product	Study Size	Structure	Sites	Status
Impact of XPERIENCE on Bone Cement Adhesion	XPERIENCE®	In-vitro & Animal study	Clinical and Laboratory collaboration	University of New South Wales Dr R Bashyal, Chicago	Study completed Paper in progress 2HFY24
Breast Augmentation	XPERIENCE®	186	Investigator Research Study (product donated). Three arms: XPERIENCE v 10% Betadine v “Triple Antibiotic Solution”	Dr A Deva Integrated Specialist Healthcare Education and Research Foundation, Australia	Study completed Paper in progress 2HFY24
Retrospective Post Operative Infection Rates	XPERIENCE®	423	Investigator Research Study XPERIENCE v standard of care	Dr. Robert Harris Jack Hughston Memorial Hospital	Paper submitted for publication 1HFY24
Retrospective Post Operative Infection Rates	XPERIENCE®	524	Next Science Study XPERIENCE v standard of care	Dr. Ron Singer The Surgery Centre at Edgewater	Paper submitted for publication 1HFY24
Retrospective Post Operative Infection Rates	XPERIENCE®	1,295	Investigator Research Study XPERIENCE v standard of care	Dr. Ravi Bashyal	Paper submitted for publication 2HFY24

# Recent Publications

Date	Area	Authors	Hyperlink
December 2023	XPERIENCE® and inflammation	Louis Battista, Andrew Wickline, MD	<a href="https://journaloei.scholasticahq.com/article/89994">https://journaloei.scholasticahq.com/article/89994</a>
December 2023	Biofilm disrupting technology (gel, wash, disinfectant)	Cox, Manavathu, Wakade, Myntti, Vazquez (Medical College of Georgia, Next Science)	<a href="https://onlinelibrary.wiley.com/doi/10.1111/myc.13684">https://onlinelibrary.wiley.com/doi/10.1111/myc.13684</a>
May 2023	SurgX® effectiveness	Kelly, Bae, et al. (The Hughston Foundation, The Hughston Clinic, Jack Hughston Memorial Hospital)	<a href="https://www.cureus.com/articles/140545-superficial-surgical-site-infections-in-primary-total-joint-arthroplasty-a-retrospective-analysis-of-topical-anti-biofilm-therapy?score_article=true#!/authors">https://www.cureus.com/articles/140545-superficial-surgical-site-infections-in-primary-total-joint-arthroplasty-a-retrospective-analysis-of-topical-anti-biofilm-therapy?score_article=true#!/authors</a>
Apr 2023	Acne treatment	Marshall-Hudson, Tuley, Damstra, Dosik, Myntti, Porral, Palomo (TXL Research Inc., Next Science)	<a href="https://pub-press.mydigitalpublication.com/publication/?m=54680&amp;i=787927&amp;p=42&amp;ver=html5">https://pub-press.mydigitalpublication.com/publication/?m=54680&amp;i=787927&amp;p=42&amp;ver=html5</a>
March 2023	Irrigation, Biofilms, Infection	Cheng, Owen , Swink, Myntti (Allegheny Health Network poster presentation at Orthopaedic Research Society meeting.	<a href="https://lnkd.in/eN3CnXv2">https://lnkd.in/eN3CnXv2</a>
March 2023	BlastX® effectiveness	Regulski, Myntti, Garth et al. (Woud Care Institute, Next Science, Montana State University)	<a href="https://www.mdpi.com/2079-6382/12/3/536">https://www.mdpi.com/2079-6382/12/3/536</a>
January 2023	Discovery: Spine Disease	Fresquez, Chung, Pereira, et al. (USC)	<a href="https://doi.org/10.1016/j.spinee.2023.01.011">https://doi.org/10.1016/j.spinee.2023.01.011</a>

# Recent Publications

Date	Area	Authors	Hyperlink
December 2022	Irrigation, Biofilms, Infection	Sosnoski, Dietz, Bou-Akl, et al. (Michigan State University)	<a href="https://pubmed.ncbi.nlm.nih.gov/36643380">https://pubmed.ncbi.nlm.nih.gov/36643380</a>
December 2022	BLASTX effectiveness	Myntti, Stevenson, Porral, et al. (Next Science)	<a href="https://pubmed.ncbi.nlm.nih.gov/36645660/">https://pubmed.ncbi.nlm.nih.gov/36645660/</a>
November 2022	Discovery: Oral Rinse	Newman, Rosebrough, Tamashiro et al. (UF Gainesville)	<a href="https://pubmed.ncbi.nlm.nih.gov/36324127/">https://pubmed.ncbi.nlm.nih.gov/36324127/</a>
October 2022	Discovery: Catheter treatment	Nvarro, Sherman, Colmer-Hamood et al. (Texas Tech)	<a href="https://pubmed.ncbi.nlm.nih.gov/36358169/">https://pubmed.ncbi.nlm.nih.gov/36358169/</a>
July 2022	Irrigation, Biofilms, Infection	Whiteley, Helms, Muire, et al. (US Army Surgical Research)	<a href="https://pubmed.ncbi.nlm.nih.gov/35840981/">https://pubmed.ncbi.nlm.nih.gov/35840981/</a>
Feb 2022	Irrigation, Biofilms, Infection	Wu, O'Donnell, Cochrane, et al. (Duke University)	<a href="https://pubmed.ncbi.nlm.nih.gov/35158106/">https://pubmed.ncbi.nlm.nih.gov/35158106/</a>
Feb 2022	Irrigation, Biofilms, Infection	Christopher, Tran, Vernon, et al. (Mayo Clinic AZ)	<a href="https://pubmed.ncbi.nlm.nih.gov/34740788/">https://pubmed.ncbi.nlm.nih.gov/34740788/</a>
Feb 2022	Irrigation, Biofilms, Infection	Bashyal, Mathew, Bowen, et al.	<a href="https://www.arthroplastyjournal.org/article/S0883-5403(22)00062-6/fulltext">https://www.arthroplastyjournal.org/article/S0883-5403(22)00062-6/fulltext</a>
Jan 2022	Irrigation, Biofilms, Infection	O'Donnell, Jams, Seyler et al. (Duke University)	<a href="https://journals.healio.com/doi/full/10.3928/01477447-20211227-05">https://journals.healio.com/doi/full/10.3928/01477447-20211227-05</a>
Dec 2021	Irrigation, Biofilms, Infection	Plate, Zuskov, Seyler (Duke University)	<a href="https://pubmed.ncbi.nlm.nih.gov/35629656/">https://pubmed.ncbi.nlm.nih.gov/35629656/</a>
Oct 2021	Irrigation, Biofilms, Infection	Knapp, Chen, Scuderi, et al. (Northwell Health & Rubin Inst)	<a href="https://pubmed.ncbi.nlm.nih.gov/35840981/">https://pubmed.ncbi.nlm.nih.gov/35840981/</a>
Sep 2021	Irrigation, Biofilms, Infection	O'Donnell, Jams, Seyler et al. (Duke University)	<a href="https://pubmed.ncbi.nlm.nih.gov/33934664/">https://pubmed.ncbi.nlm.nih.gov/33934664/</a>
May 2021	Irrigation, Biofilms, Infection	Kia, Cusano, Messina, et al. (University of Connecticut)	<a href="https://pubmed.ncbi.nlm.nih.gov/33529773/">https://pubmed.ncbi.nlm.nih.gov/33529773/</a>

This presentation has been prepared by Next Science Limited ACN 622 382 549 (Company) and is provided for general information purposes only. It is not a product disclosure statement, pathfinder document or any other disclosure document for the purposes of the Corporations Act 2001 (Cth) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission (ASIC). It should not be relied upon by the recipient in considering the merits of the Company or the acquisition of shares in the Company. This presentation should not be considered an offer or an invitation to acquire or sell, or a solicitation to invest in or refrain from investing in, new shares in the Company or any other financial products.

This document has been prepared based on information available as at the date of this presentation. It contains selected summary information and does not purport to be all-inclusive, comprehensive or to contain all of the information that may be relevant or which a prospective investor may require in evaluations for a possible investment in the Company. It should be read in conjunction with the Company's periodic and continuous disclosure announcements which are available at [www.nextscience.com](http://www.nextscience.com) and [www.asx.com.au](http://www.asx.com.au). The recipient acknowledges that circumstances may change and that this presentation may become outdated as a result. This presentation and the information in it are subject to change without notice. The Company is not obliged to update this presentation.

The information contained in this presentation does not constitute investment, legal, tax, accounting or financial product advice nor any recommendation to acquire securities in the Company. This presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, the recipient should consider its own financial situation, objectives and needs, and conduct its own independent investigation and assessment of the contents of this presentation, including obtaining investment, legal, tax, accounting and such other advice as it considers necessary or appropriate. Any references to or explanations of legislation, regulatory issues, benefits or any other legal commentary (if any) are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. The information in this presentation has been obtained from and based on sources believed by the Company to be reliable. Past performance is not an indication of future performance.

This presentation may contain forward-looking statements, guidance, forecasts, estimates, prospects, projections or statements in relation to future matters that may involve risks or uncertainties and may involve significant items of subjective judgement and assumptions of future events that may or may not eventuate (Forward Statements). Forward Statements can generally be identified by the use of forward looking words such as "anticipate", "estimates", "will", "should", "could", "may", "expects", "plans", "forecast", "target" or similar expressions. Forward Statements including indications, guidance or outlook on future revenues, distributions or financial position and performance or return or growth in underlying investments are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No independent third party has reviewed the reasonableness of any such statements or assumptions. None of the Company, its related bodies corporate and their respective officers, directors, employees, advisers, partners, affiliates and agents (together, the Next Science Parties) represent or warrant that such Forward Statements will be achieved or will prove to be correct or gives any warranty, express or implied, as to the accuracy, completeness, likelihood of achievement or reasonableness of any Forward Statement contained in this presentation. Except as required by law or regulation, the Company assumes no obligation to release updates or revisions to Forward Statements to reflect any changes. Recipients should form their own views as to these matters and any assumptions on which any of the Forward Statements are based and not place reliance on such statements.

All dollar values are in \$USD unless stated otherwise.

An investment in Company shares is subject to investment and other known and unknown risks, some of which are beyond the control of the Company, including factors and risks specific to the industry in which Next Science operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. The Company does not guarantee any particular rate of return on its performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes may have on the Company.

The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate applicable securities law.

No party other than the Company has authorised, permitted or caused the issue, submission, dispatch or provision of this presentation, or takes any responsibility for, or makes or purports to make any statement, representation or undertaking in this presentation and there is no statement in this presentation that is based on any statement by any other party. No person, either as a director or partner of, or in the employment of, the Company has any authority to make, imply, or give any representation or warranty whatsoever in relation to the information contained in this presentation. None of the Next Science Parties take any responsibility for any information in this presentation or any action taken by you on the basis of such information. To the maximum extent permitted by law, the Next Science Parties: exclude and disclaim all liability, including (without limitation) any liability for fraud or negligence, for any expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation; and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.



**Approved by the Board**

Next Science Limited ABN 47 622 382 549  
Level 14, Australia Square,  
264-278 George Street , Sydney NSW 2000

**NEXT SCIENCE®**